Axis Securities has issued a Buy rating for Biocon, setting a target price of Rs 424. The brokerage highlights Biocon's recent EMA approval for its Malaysian insulin facility, which doubles manufacturing capacity. With a shift toward debt reduction, improving biosimilar margins, and new product launches like bAflibercept and bDenosumab, analysts expect significant margin acceleration starting in the second half of FY27.
Axis Securities Issues Buy Rating for Biocon
Target Price: Rs 424 | CMP: Rs 385
Reader Takeaway: Capacity expansion in Malaysia and debt reduction drive long-term margin growth and balance sheet health.
What just happened
Axis Securities has initiated coverage on Biocon with a Buy rating, setting a price target of Rs 424. The brokerage projects a 10% upside from the current market price of Rs 385 over a 6 to 9-month investment horizon. The analysis centers on the company’s recent operational milestones and structural financial improvements.
Why this matters
The company’s European Medicines Agency (EMA) approval for its second drug product line at the Malaysian insulin facility is a major catalyst. This move effectively doubles capacity and facilitates commercial supply from Q2FY27. Additionally, the company is seeing a reduction in interest expenses, which fell 23% year-over-year, following the retirement of structured debt.
What changes now
Investors should look for the impact of higher capacity utilization on margins, particularly as the biosimilars segment hits its mid-20s EBITDA margin targets. The launch of bAflibercept and bDenosumab in Western markets is expected to provide top-line support as the company shifts its focus toward higher-growth biopharma products and balance sheet deleveraging.
Context metrics
Brokerage estimates show net sales growth reaching Rs 22,344 crore by FY28, with net profit forecasted to rise significantly to Rs 1,839 crore in the same period compared to Rs 369 crore in FY26. Earnings per share (EPS) are projected to climb from Rs 2.3 in FY26 to Rs 11.3 by FY28.
What to track next
Watch for the ramp-up in H2FY27 as the expanded insulin capacity comes fully online. Further, market share gains in Insulin Glargine and the performance of GLP-1 generic Liraglutide will be critical performance indicators for the stock.